Literatur
-
1
Desch C E, Benson A B, Smith T J, Flynn P J, Krause C, Loprinzi C L, Minsky B D, Petrelli N J, Pfister D G, Somerfield M R.
Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology.
J Clin Oncol.
1999;
17
1312-1321
-
2
Temple L KF, Wang E EL, McLeod R S. with the Cancadian Task Force on Preventive Health Care .
Preventive Health Care, 1999 update: 3. Follow-up after breast cancer.
Can Med Assoc J.
1999;
161
1001-1008
-
3
Hayes D F, Bast R C, Desch C E, Fritsche H H, Kemeny N E, Jessup J M, Locker G Y, Macdonald J S, Mennel R G, Norton L, Ravdin P, Taube S, Winn R J.
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
J Natl Cancer Inst.
1996;
88
1456-1466
-
4
Hayes D F, Bast R, Desch C E, Fritsche H, Kemeny N E, Jessup J M, Locker G Y, Macdonald J S, Mennel R G, Norton L, Ravdin P, Taube S, Winn R J.
A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers.
J Natl Cancer Inst.
1996;
88
1456-1466
-
5 Ausführliche Literatursammlung unter www.ago-online.de.
-
6
Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep C G, Selbmann H K, Graeff H, Schmitt M. for the German Chemo N0 Study Group .
Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I.
J Natl Cancer Inst.
2001;
93
913-920
-
7
Early Breast Cancer Trialists' Collaborative Group .
Tamoxifen for early breast cancer: An overview of the randomized trials.
Lancet.
1998;
351
1451-1467
-
8
Mass R, Press M, Anderson S, Slamon D.
Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridisation.
Breast Canc Res Treat.
2001;
69 (Abstract 18)
213
-
9
EUSOMA .
The requirements of a specialist breast unit.
Eur J Cancer.
2000;
36
2288-2293
-
10
Perry N M. on behalf of the EUSOMA Working Party .
Quality assurance in the diagnosis of breast disease.
Eur J Cancer.
2001;
37
159-172
-
11
Rutgers E JTH. for the EUSOMA Consensus Group .
Position Paper EUSOMA Guidelines: Quality control in the locoregional treatment of breast Cancer.
Eur J Cancer.
2001;
37
447-453
-
12
Samant R, Ganguly P.
Staging investigations in patients with breast cancer: the role of bone scans and liver imaging.
Arch Surg.
1999;
134
551-553
-
13
Renton S C, Garet I C, Ford H T, Corbishley C, Sutcliffe R.
The importance of the resection margin in conservative surgery for breast cancer.
Eur J Surg Oncol.
1996;
22
17-22
-
14
Bilchert-Toft M, Smola M G, Cataliotti L, O'Higgins N. . European Society of Surgical Oncology .
Principles and guidelines for surgeons - management of symptomatic breast cancer.
Eur J Surg Oncol.
1997;
23
101-109
-
15
Dixon J M, Ravisekar O, Cunningham M, Anderson E D, Anderson T J, Brown H K.
Factors affecting outcome of patients with impalpable breast cancer detected by breast screening.
Br J Surg.
1996;
83
997-1001
-
16
Cady B.
A contemporary view of axillary dissection.
Ann Surg.
2000;
232
8-9
-
17
Recht A.
Should irradiation replace dissection for patients with breast cancer with clinically negative axillary lymph nodes?.
J Surg Oncol.
1999;
72
184-192
-
18
Van de Steene J, Soete G, Storme G.
Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link.
Radiother Oncol.
2000;
55
263-272
-
19
Fein D A, Fowble B L, Hanlon A L. et al .
Identification of women with T1 - T2 breast cancer at low risk of positive axillary nodes.
J Surg Oncol.
1997;
65
34-39
-
20
Maibenco D C, Weiss L K, Pawlish K S, Severson R K.
Axillary lymph node metastases associated with small invasive breast carxinomas.
Cancer.
1999;
85
1530-1536
-
21
Silver S A, Tavassoli F A.
Mammary ductal carcinoma in situ with microinvasion.
Cancer.
1998;
82
2382-2390
-
22
Audretsch W, Rezai M, Kolotas Ch, Zamboglou N, Schnabel T, Bojar H.
Tumor-specific immediate reconstruction (TSIR) in breast cancer patients.
Perspectives in Plast Surg.
1998;
11
1
-
23
Kroll S S, Khoo A, Singletary S E, Ames F C, Wang B G, Reece G P, Miller M J, Evans G R, Rob G L.
Local Recurrence Risk after Skin-Sparing and Conventional Mastectomy: a 6-Year Follow-Up.
Plast Reconstr Surg.
1999;
104
421-425
-
24
Calabrese C, Distante V, Orzalesi L. et al .
Immediate reconstruction with mammaplasty in conservative breast cancer treatment: Long-term results.
Focus Rec Breast Cancer Surg Osp Ital Chir.
2001;
7
38-46
-
25
Vandeweyer E, Deraemaecker R.
Radiation Therapy after Immediate Breast Reconstruction with Implants.
Plast Reconstr Surg.
2000;
106
56
-
26
Williams J K, Carlson GW, Bostwick J, Bried J T, Mackay G.
The effects of radiation after TRAM flap breast reconstruction.
Plast Reconstr Surg.
1997;
100
1153
-
27
Ernster V L, Barclay J, Kerlikowske K. et al .
Incidence of and treatment for ductal carcinoma in situ of the breast .
JAMA.
1996;
275
913-918
-
28
Page D L, Dupont W D, Rogers L W. et al .
Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy.
Cancer.
1995;
76
1197-1200
-
29
Bijker N, Peterse J L, Duchateau L. et al .
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.
J Clin Oncol.
2001;
19
2263-2271
-
30
Silverstein M J, Poller D N, Waisman J R. et al .
Prognostic classification of breast ductal carcinoma-in-situ.
Lancet.
1995;
345
1154-1157
-
31
Silverstein M J, Lagios M D, Groshen S. et al .
The influence of margin width on local control of ductal carcinoma in situ of the breast.
N Engl J Med.
1999;
340
1455-1461
-
32
Fisher B, Dignam J, Wolmark N. et al .
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.
J Clin Oncol.
1998;
16
441-452
-
33
Julien J P, Bijker N, Fentiman I S. et al .
Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
Lancet.
2000;
355
528-533
-
34
Fisher B, Dignam J, Wolmark N.
et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial.
Lancet.
1999;
353
1993-2000
-
35
Early Breast Cancer Trialists' Collaborative Group .
Polychemotherapy for early breast cancer: An overview of the randomized trials.
Lancet.
1998;
352
930-942
-
36
Henderson I C, Berry D, Demetri G, Cirrincione C. et al .
Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC).
Proc ASCO.
1998;
17
390 A (abstract)
-
37 Mamounas E P. Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axilary nodes. NIH Consensus Development Conference on adjuvant therapy for breast cancer. Bethesda 2000
-
38
Bonadonna G, Valagussa P, Moliterni A. et al .
Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in node-positive breast cancer.
N Engl J Med.
1995;
332
901-906
-
39
Engelsman E, Klijn J GM, Rubens R D. et al .
“Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer.
Eur J Cancer.
1991;
27
966-970
-
40
Levine M N, Bramwell V H, Pritchard K I, Shepherd L E. et al .
Randomized Trial of Intensive Cyclophosphamide, Epirubicin, and Fluorouracil Chemotherapy Compared with Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women with Node-Positive Breast Cancer.
J Clin Oncol.
1998;
16
2651-2658
-
41
Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins J N, Fehrenbacher L, Henry P H, Romond E H, Lanier K S, Davila E, Kardinal C G, Laufman L, Pierce H I, Abramson N, Keller A M, Hamm J T, Wickerham D L, Begovic M, Tan-Chiu E, Tian W, Wolmark N.
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.
J Clin Oncol.
1999;
17
3374-3388
-
42
Baum M. on behalf of the ATAC Trialists’ Group .
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women.
Breast Canc Res Treat.
2001;
69
210 (abstract 8)
-
43 Early Breast Cancer Trialists’ Collaborative Group .Ovarian ablation for early breast cancer (Cochrane Review). In: The Cochrane Library, 3, 2001. Oxford: Update Software
-
44
Kaufmann M, von Minckwitz G.
The emerging role of hormonal ablation.
The Breast.
2001;
10 (Suppl 3)
123-129
-
45
Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Depisch E, Fridrik M, Stierer M, Gnant M, Steger G, Kolb R, Jatzko G, Hofbauer F, Reiner G, Luschin-Ebengreuth G.
Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four year results of ABCSG trial 5.
Proc ASCO.
1999;
18
67 A
-
46
Honkoop A H, Wagstaff J, Pinedo H M.
Management of stage III breast cancer.
Oncology.
1998;
55
218-227
-
47
Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese R G, Cruz A B, Fisher E R, Wickerham D L, Wolmark N, DeCillis A, Hoehn J L, Lees A W, Dimitrov N V.
Effect of Preoperative Chemotherapy on Local-Regional Disease in Women With Operable Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-18.
J Clin Oncol.
1997;
15
2483-2493
-
48 Kaufmann M, von Minckwitz G, Smith R, Valero V, Costa S D, Howell A, Souchon R, Untch M, Beuzeboc P, Gianni L, Senn H J. International Consensus Panel on the Primary Systemic Treatment of Breast Cancer - Meeting Highlights and Recommendations. In prep
-
49
Berry D L, Theriault R L, Holmes F A, Parisi V M, Booser D J, Singletary S E, Buzdar A U, Hortobagyi G N.
Management of breast cancer during pregnancy using a standardized protocol.
J Clin Oncol.
1999;
17
855-861
-
50
Ellis M J, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller W R, Evans D B, Dugan M, Brady C, Quebe-Fehling E, Borgs M.
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
J Clin Oncol.
2001;
19
3808-3816
-
51
Slamon D J, Leyland-Jones D, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L.
Use of Chemotherapy plus a monoclonal Antibody against HER2 for metastatic Breast Cancer that overexpresses HER2.
N Engl J Med.
2001;
344
783-792
-
52
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwskowki M, Coombs D, Baly D, Kabbinavar F, Slamon D.
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Oncogene.
1999;
18
2241-2251
-
53
Baselga J.
Safety profile of Herceptin as a single agent and in combination with chemotherapy.
ECCO.
1999;
9
Abstr. 1299
-
54
Sledge G W. et al .
Cisplatin as first-line therapy for metastatic breast cancer.
J Clin Oncol.
1988;
6
811-1814
-
55
O'Brien M E. et al .
Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule.
J Clin Oncol.
1993;
11
2112-2117
-
56
Pienkowski T, Fumoleau P, Eiermann W, Crown J, Smylie M, Klimo P, Martin L A, von Minckwitz G, Prady C, Riva A, Slamon D, Nabholtz J M.
Taxotere, Cisplatin and Herceptin (TCH) in First-Line HER2 Positive Metastatic Breast Cancer (MBC) Patients, a Phase II Pilot Study by the Breast Cancer International Research Group (BCIRG 101).
Proc Asco.
2001;
20
2030
-
57
Hillner B E, Ingle J N, Berenson J R, Janjan N A, Albain K S, Lipton A, Yee G, Biermann J S, Chlebowski R T, Pfister D G.
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
J Clin Oncol.
2000;
18
1378-1391
-
58
Diel I J, Solomayer E F, Costa S D, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G.
Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
N Engl J Med.
1998;
339
357-363
-
59
Saarto T, Blomqvist C, Virkkunen P, Elomaa I.
Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.
J Clin Oncol.
2001;
19
10-17
-
60
Powles T J, Paterson A H, McCloskey E, Ashley S, Tidy V A, Kanis J A, Pylkkkänen I.
A randomized placebo controlled trial to evaluate the effect of the bisphosphonate, clodronate, on the incidence of metastases and mortality in patients with primary operable breast cancer.
Breast Canc Res Treat.
2001;
69
209 (abstract 1)
-
61
Fisher B, Anderson S, Redmond C K, Wolmark N, Wickerham D L, Cronin W M.
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.
N Engl J Med.
1995;
333
1456-1461
-
62
Bartelink H, Horiot J C, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M.
European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.
N Engl J Med.
2001;
345
1378-1387
-
63
Vrieling C, Collette L, Fourquet A, Hoogenraad W J, Horiot J H, Jager J J, Pierart M, Poortmans P M, Struikmans H, Maat B, Van Limbergen E, Bartelink H. . EORTC Radiotherapy and Breast Cancer Cooperative Groups. .
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial.
Radiother Oncol.
2000;
55
219-32
-
64
Bartelink H, Horiot J-C, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M,. the European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups .
Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.
N Engl J Med.
2001;
345
1378-1387
-
65
Recht A, Edge S B, Solin L J, Robinson D S, Estabrook A, Fine R E, Fleming G F, Formenti S, Hudis C, Kirshner J J, Krause D A, Kuske R R, Langer A S, Sledge G W, Whelan T J, Pfister D G.
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.
J Clin Oncol.
2001;
19
1539-1569
-
66
Early Breast Cancer Trialists’ Collaborative Group .
Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials.
Lancet.
2000;
355
1757-1770
-
67
Tennvall-Nittby L, Tengrup I, Landberg T.
The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer Trial.
Acta Oncol.
1993;
32
641-646
-
68
Recht A, Come S E, Henderson I C, Gelman R S, Silver B, Hayes D F, Shulman L N, Harris J R.
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.
N Engl J Med.
1996;
334
1356-1361
-
69
Gnant M,. on behalf of the Austrian Breast & Colorectal Cancer Study Group (ABCSG) .
Impact of Participation in Randomized Clinical Trials on Survival of Women with Early-Stage Breast Cancer - An Analysis of 7 985 Patients.
Proc ASCO.
2000;
Abst 287
-
70
Fisher B, Anderson S.
Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials.
World J Surg.
1994;
18
63-69
-
71
Fisher B, Anderson S, Redmond C K, Wolmark N, Wickerham D L, Cronin W M.
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.
New Engl J Med.
1995;
333
1456-1461
-
72 NSABP .The effect on primary tumor response of adding sequential taxotere to adriamycin and cylophosphamide: preliminary results from NSABP Protocol B-27. San Antonio Breast Cancer Symposium 2001
Priv. Doz. Dr. med. G. von MinckwitzSprecher der Organkommission „Mamma”
Universitätsklinikum Frankfurt
Klinik für Frauenheilkunde und Geburtshilfe
Theodor-Stern-Kai 7
60590 Frankfurt
Phone: 0 69/63 01 70 24
Fax: 0 69/63 01 79 38
Email: minckwitz@em.uni-frankfurt.de
